Immunotherapy: balancing the risks and benefits – an excellent editorial on issues in oncology practice

Immunotherapy: balancing the risks and benefits – an excellent editorial on issues in oncology practice

Immunotherapy has become one of the most widely used interventions for treating patients with cancer and continues to be a fertile area of research with new targets, drug classes, and combination therapies being discovered regularly.

Immunotherapy with immune checkpoint inhibitors has improved patient outcomes as measured by overall survival.  This comes with issues involving immune reactions. This paper shows the importance of understanding that new classes of drugs have different types of side effects (and with ICIs, well described in guidelines produced by ASCO).  The point is made that therapy to control these SAEs may result in poorer survival.

READ THE ARTICLE – https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00028-7/fulltext

Share this post